AI Stocks Retreat From Highs As Hype Fades for Recursion, C3.ai

Recursion Pharmaceuticals stock surged on a partnership with Nvidia, but has since retreated as the AI hype dies down. The clinical-stage company is very risky.

C3.ai is focused on AI but hasn't delivered impressive growth despite management hype.

C3.ai is struggling to attract customers organically and now plans to invest heavily in marketing and lead generation.

C3.ai previously projected profitability soon but has pushed back that timeline to invest more in marketing.

Both Recursion and C3.ai saw their stocks surge earlier this year due to AI excitement, but are risky buys after retreating from highs.